---
title: "ELV: Raised 2026 EPS guidance to at least $27.00 after strong Q2 performance and targeted investments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292747568.md"
description: "Second quarter results exceeded expectations with strong operating performance and improved benefit expense ratio. Adjusted diluted EPS was $7.45, and 2026 EPS guidance was raised to at least $27.00, supported by non-recurring benefits funding targeted investments.Original document: Elevance Health, Inc. [ELV] Slides Release — Jul. 15 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-15T10:05:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292747568.md)
  - [en](https://longbridge.com/en/news/292747568.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292747568.md)
---

# ELV: Raised 2026 EPS guidance to at least $27.00 after strong Q2 performance and targeted investments

Second quarter results exceeded expectations with strong operating performance and improved benefit expense ratio. Adjusted diluted EPS was $7.45, and 2026 EPS guidance was raised to at least $27.00, supported by non-recurring benefits funding targeted investments.

Original document: Elevance Health, Inc. \[ELV\] Slides Release — Jul. 15 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Bessemer Group Inc. Has $1.26 Million Holdings in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/293717109.md)
- [Elevance Health CEO Gail Boudreaux acquires common shares worth $1,003,428.45](https://longbridge.com/en/news/293064111.md)
- [STEAV: Q2 2026 EBIT rose 27% year-over-year, supported by portfolio actions and Oulu ramp-up](https://longbridge.com/en/news/293580139.md)
- [WH: Q2 2026 delivered strong RevPAR, room growth, and margins, with a positive 2026 outlook](https://longbridge.com/en/news/293549537.md)
- [Elevance Health reports Q2 2026: Revenue $49.8B, Adj. diluted EPS $7.45, raises FY guidance](https://longbridge.com/en/news/292749073.md)